In addition, CCL5 has been shown to increase αvβ3 integrin expression in cancer cells and increase NF-κB-mediated resistance to drug-induced apoptosis, thus facilitating enhanced integrin-mediated tumor invasion and an immunosuppressive, anti-apoptotic tumor microenvironment [60–63]. This evidence concerns the gene CCL5 and cancer.